Cargando…

Von Willebrand disease type 2M: Correlation between genotype and phenotype

BACKGROUND: An appropriate clinical diagnosis of von Willebrand disease (VWD) can be challenging because of a variable bleeding pattern and laboratory phenotype. Genotyping is a powerful diagnostic tool and may have an essential role in the diagnostic field of VWD. OBJECTIVES: To unravel the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maas, Dominique P. M. S. M., Atiq, Ferdows, Blijlevens, Nicole M. A., Brons, Paul P. T., Krouwel, Sandy, Laros‐van Gorkom, Britta A. P., Leebeek, Frank W. G., Nieuwenhuizen, Laurens, Schoormans, Selene C. M., Simons, Annet, Meijer, Daniëlle, van Heerde, Waander L., Schols, Saskia E. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	HAEMOSTASIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299039/ https://www.ncbi.nlm.nih.gov/pubmed/34758185 http://dx.doi.org/10.1111/jth.15586

Ejemplares similares

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2022)

Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype
por: Atiq, Ferdows, et al.
Publicado: (2022)

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2022)

Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma
por: Maas, Dominique, et al.
Publicado: (2018)

Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients
por: Swinkels, Maurice, et al.
Publicado: (2022)

Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield
por: Valke, Lars L. F. G., et al.
Publicado: (2022)

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
por: Pagliari, Maria Teresa, et al.
Publicado: (2022)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Sports participation and physical activity in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease
por: Boender, Johan, et al.
Publicado: (2021)

SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
por: Cnossen, Marjon H., et al.
Publicado: (2022)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

How I manage severe von Willebrand disease
por: Leebeek, Frank W. G., et al.
Publicado: (2019)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms
por: Sacco, Monica, et al.
Publicado: (2022)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
por: Buijs, Jeroen T., et al.
Publicado: (2019)

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
por: Punt, Marieke C., et al.
Publicado: (2020)

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
por: Peyvandi, F., et al.
Publicado: (2018)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device‐induced acquired von Willebrand syndrome
por: Deconinck, Shannen, et al.
Publicado: (2018)

Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin‐K antagonists: A randomized controlled trial
por: Mertens, Bram J., et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease
por: von Meijenfeldt, Fien A., et al.
Publicado: (2020)

Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis
por: van den Boom, Bente P., et al.
Publicado: (2021)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations
por: Temprano‐Sagrera, Gerard, et al.
Publicado: (2022)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3kn74sda4s2543v1cqcrh945dt